Mobile C-arm manufacturer OEC Medical Systems last week postedlower income and revenues for its 1994 fiscal year (end-December).The Salt Lake City company said market pressures and delays inshipping its new Series 9600 mobile C-arm may have affected
Mobile C-arm manufacturer OEC Medical Systems last week postedlower income and revenues for its 1994 fiscal year (end-December).The Salt Lake City company said market pressures and delays inshipping its new Series 9600 mobile C-arm may have affected itsfinancial numbers.
Despite the dip, OEC was profitable last year by a wide margin.Revenues for the year were $98.2 million, a drop of 1.8% overthe $100 million in sales recorded in 1993. Net income was $8.7million, 11% lower than the $9.8 million registered in the previousyear.
OEC president and CEO David Rose said the company experiencedshipping delays in the second quarter for Series 9600. In addition,the company's year-end backlog has decreased by about one-thirdover last year due to lengthening sales cycles and market pressures.Still, OEC is experiencing increased acceptance of Series 9600and the company has successfully reduced operating expenses, accordingto Rose.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.